https://longevity.technology/news/altimmunes-pemvidutide-earns-fda-breakthrough-status/
Altimmune’s pemvidutide earns FDA breakthrough status
Jan 13, 2026 - FDA designation fast-tracks a promising therapy for MASH, a silent liver disease tied to metabolic aging and long-term health.
breakthrough statuspemvidutideearnsfda